keyword
MENU ▼
Read by QxMD icon Read
search

Advanced lung cancer

keyword
https://www.readbyqxmd.com/read/29454155/immune-checkpoint-inhibitors-in-non-small-cell-lung-cancer-nsclc-approaches-on-special-subgroups-and-unresolved-burning-questions
#1
REVIEW
J Remon, N Vilariño, N Reguart
Immune checkpoint inhibitors (ICIs) have been incorporated in the treatment strategy of advanced non-small cell lung cancer (NSCLC). Beyond the already approved indications in first- and second-line setting of advanced NSCLC, new data has recently emerged demonstrating its efficacy in locally advanced disease as maintenance after chemo-radiotherapy and currently several trials are also exploring its efficacy in earlier stages of the disease to evaluate whether these results could be extrapolated to the adjuvant setting...
February 8, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29452098/features-of-chronic-obstructive-pulmonary-disease-as-predictors-of-lung-cancer
#2
Laurie L Carr, Sean Jacobson, David A Lynch, Marilyn G Foreman, Eric L Flenaugh, Craig P Hersh, Frank C Sciurba, David O Wilson, Jessica C Sieren, Patrick Mulhall, Victor Kim, C Matthew Kinsey, Russell P Bowler
BACKGROUND: Lung cancer is a leading cause of death and hospitalization for patients with chronic obstructive lung disease, (COPD); a detailed understanding of which clinical features of COPD increase risk is needed. METHODS: To identify clinical and imaging features of smokers, with and without COPD, that are associated with an increased risk of lung cancer, we performed a nested case-control study of COPDGene subjects with and without lung cancer, age 45-80, who smoked at least 10-pack years...
February 13, 2018: Chest
https://www.readbyqxmd.com/read/29452091/expression-profiles-and-clinical-value-of-plasma-exosomal-tim-3-and-galectin-9-in-non-small-cell-lung-cancer
#3
Jianwei Gao, Xiangyu Qiu, Xinying Li, Hang Fan, Fang Zhang, Tangfeng Lv, Yong Song
Exosomes are membrane-bound, virus-size vesicles present in circulating blood. Tumor cells are avid producers of exosomes, which are thought to mimic molecular features of parent tumor cells. T-cell Immunoglobulin- and Mucin-domain-containing molecule 3 (Tim-3) is one of the next generation immune checkpoints and can be activated by its ligand Galectin-9, negatively regulating anti-tumor immune response. However, the characteristics of plasma exosomal Tim-3/Galectin-9 (Exo-T/G) in cancer remained unknown. Our study aimed to investigate the expression patterns and clinical value of plasma exosomal total protein (Exo-pro) and Exo-T/G in non-small cell lung caner (NSCLC)...
February 13, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29451718/kiaa0247-inhibits-growth-migration-invasion-of-non-small-cell-lung-cancer-through-regulating-the-notch-pathway
#4
Yitong Xu, Hongjiu Ren, Jun Jiang, Qiongzi Wang, Muli Wudu, Qingfu Zhang, Hongbo Su, Chenglong Wang, Lihong Jiang, Xueshan Qiu
Lung cancer remains the leading cause of cancer-related death worldwide. Previous studies have shown that the novel KIAA0247 gene potentially targeted by the tumor suppressor p53 may inhibit the development of several cancers. However, the exact function of KIAA0247 in non-small-cell lung cancer (NSCLC) is unknown. The purpose of this study was to clarify the role of KIAA0247 in NSCLC. KIAA0247 expression was evaluated in tumors and adjacent normal tissues of 197 NSCLC patients by immunohistochemistry and real-time PCR and analyzed for association with clinicopathological parameters...
February 16, 2018: Cancer Science
https://www.readbyqxmd.com/read/29451696/randomized-phase-2-trial-of-pemetrexed-pemetrexed-bevacizumab-and-pemetrexed-carboplatin-bevacizumab-in-patients-with-stage-iiib-iv-non-small-cell-lung-cancer-and-an-eastern-cooperative-oncology-group-performance-status-of-2
#5
David R Spigel, John D Hainsworth, Mathew J Joseph, Dianna L Shipley, M Kelly Hagan, Dana S Thompson, Howard A Burris, F Anthony Greco
BACKGROUND: The best treatment for patients with advanced non-small cell lung cancer (NSCLC) and a poor performance status is not well defined. In this phase 2 trial, patients were randomized to receive treatment with either single-agent pemetrexed or 1 of 2 combination regimens. METHODS: Patients with newly diagnosed, histologically confirmed nonsquamous NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 were stratified by age and serum albumin level and were randomized (1:1:1) to 1 of 3 regimens: pemetrexed (arm 1), pemetrexed and bevacizumab (arm 2), or pemetrexed, carboplatin, and bevacizumab (arm 3)...
February 16, 2018: Cancer
https://www.readbyqxmd.com/read/29451020/the-brigatinib-experience-a-new-generation-of-therapy-for-alk-positive-non-small-cell-lung-cancer
#6
Idoroenyi Amanam, Rohan Gupta, Isa Mambetsariev, Ravi Salgia
Lung cancer remains the leading cause of cancer deaths in the world with 1.69 million deaths in 2015. A total of 85% of lung cancer cases are non-small-cell lung cancers (NSCLCs). Driver mutations associated with anaplastic lymphoma kinase (ALK) have been identified in a variety of malignancies, including NSCLC. An ALK inhibitor (crizotinib, ceritinib and alectinib) is the preferred therapeutic approach to those advanced ALK fusion variant-positive NSCLC patients. Brigatinib, a next-generation ALK inhibitor, shows promising activity in ALK-rearranged NSCLC that have previously received crizotinib with response rates in ALTA ranging from 42-50%, intracranial response 42-67% and median progression-free survival 9...
February 16, 2018: Future Oncology
https://www.readbyqxmd.com/read/29450203/real-life-experience-of-ceritinib-in-crizotinib-pretreated-alk-advanced-non-small-cell-lung-cancer-patients
#7
Jacques Cadranel, Alexis B Cortot, Hervé Lena, Bertrand Mennecier, Pascal Do, Eric Dansin, Julien Mazieres, Christos Chouaid, Maurice Perol, Fabrice Barlesi, Gilles Robinet, Sylvie Friard, Luc Thiberville, Clarisse Audigier-Valette, Alain Vergnenegre, Virginie Westeel, Khemaies Slimane, Alexandru Buturuga, Denis Moro-Sibilot, Benjamin Besse
Here we report our experience of ceritinib in crizotinib-pretreated patients with anaplastic lymphoma kinase ( ALK ) positive ( ALK + ) non-small cell lung cancer (NSCLC) in a French temporary authorisation for use (TAU) study. The French TAU study included crizotinib-pretreated patients with advanced ALK + or ROS proto-oncogene 1 positive ( ROS1 + ) tumours. Patients received oral ceritinib (750 mg·day -1 as a starting dose) and best tumour response (as evaluated by the investigator) and safety were reported every 3 months...
January 2018: ERJ Open Research
https://www.readbyqxmd.com/read/29449898/targeted-therapy-of-brain-metastases-latest-evidence-and-clinical-implications
#8
REVIEW
Rodica Di Lorenzo, Manmeet S Ahluwalia
Brain metastases (BM) occur in 20-40% of patients with cancer and 60-75% of patients with BM become symptomatic. Due to an aging population and advances in the treatment of primary cancers, patients are living longer and are more likely to experience complications from BM. The diagnosis of BM drastically worsens long-term survival rates, with multiple metastases being a poor prognostic factor. Until recently, the mainstay of treatment consisted of stereotactic radiosurgery (SRS), surgical resection, whole brain radiation therapy (WBRT), or a combination of these modalities...
December 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29449897/atezolizumab-feasible-second-line-therapy-for-patients-with-non-small-cell-lung-cancer-a-review-of-efficacy-safety-and-place-in-therapy
#9
REVIEW
Fanny Jean, Pascale Tomasini, Fabrice Barlesi
Advanced non-small cell lung cancer (NSCLC) prognosis is still poor and has recently been reformed by the development of immune checkpoint inhibitors and the approval of anti-PD-1 (programmed cell-death 1) treatments such as nivolumab and pembrolizumab in second line. More recently, atezolizumab (MDPL 3280A), a programmed cell-death-ligand 1 (PD-L1) inhibitor, was also studied in this setting. Here, we report a review of the literature assessing the efficacy, safety, and place of atezolizumab in the second-line treatment of advanced NSCLC...
December 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29449540/s100a4-promotes-lung-tumor-development-through-%C3%AE-catenin-pathway-mediated-autophagy-inhibition
#10
Shasha Hou, Tian Tian, Dianwen Qi, Kaiji Sun, Qi Yuan, Ziling Wang, Zhihai Qin, Zhenlong Wu, Zhinan Chen, Jinhua Zhang
Autophagy has emerged as a critical pathway in tumor development. S100A4 plays important roles in tumor metastasis, but its role in regulating autophagy has not been well characterized. In this study, we found that S100A4 was significantly upregulated in lung adenocarcinoma tissues. Clinical investigation demonstrated that high expression level of S100A4 was associated with tumor size and advanced tumor grades of lung adenocarcinoma patients. Moreover, our results revealed that extracellular S100A4 or overexpression of S100A4 inhibited starvation-induced autophagy and promoted cell proliferation in lung cancer cells in vitro; whereas small interfering RNA (siRNA)-mediated suppression of S100A4 increased autophagy and reduced cell viability in both A549 and LLC cells...
February 15, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29447258/the-time-series-behavior-of-neutrophil-to-lymphocyte-ratio-is-useful-as-a-predictive-marker-in-non-small-cell-lung-cancer
#11
Tatsunori Kiriu, Masatsugu Yamamoto, Tatsuya Nagano, Daisuke Hazama, Reina Sekiya, Masahiro Katsurada, Daisuke Tamura, Motoko Tachihara, Kazuyuki Kobayashi, Yoshihiro Nishimura
BACKGROUND: Nivolumab improves the survival of advanced non-small cell lung cancer (NSCLC), but a significant number of patients still fail to benefit from this treatment. In this study, we evaluated the efficacy of the time-series behavior of neutrophil-to-lymphocyte ratio (NLR) in a complete blood count from advanced NSCLC patients as a predictive marker of the anticancer effect of nivolumab. METHODS: We performed a retrospective review of medical records and collected data on patients with advanced NSCLC treated with nivolumab as second- and further-line treatments from December 2015 to March 2017...
2018: PloS One
https://www.readbyqxmd.com/read/29446317/credentialing-of-radiotherapy-centres-in-australasia-for-trog-09-02-chisel-a-phase-iii-clinical-trial-on-stereotactic-ablative-body-radiotherapy-of-early-stage-lung-cancer
#12
Tomas Kron, Brent Chesson, Nicholas Hardcastle, Melissa Crain, Natalie Clements, Mark Burns, David Ball
OBJECTIVE: A randomised clinical trial comparing Stereotactic Ablative Body Radiotherapy (SABR) with conventional radiotherapy for early stage lung cancer has been conducted in Australia and New Zealand under the auspices of the TransTasman Radiation Oncology Group (NCT01014130). We report on the technical credentialing program as prerequisite for centres joining the trial. METHODS: Participating centres were asked to develop treatment plans for two test cases to assess their ability to create plans according to protocol...
February 15, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29445889/clinical-significance-of-circulating-tumor-cells-from-lung-cancer-patients-using-microfluidic-chip
#13
Chen Qian, Shan Wu, Hongmei Chen, Xiaofen Zhang, Rongrong Jing, Lei Shen, Xudong Wang, Shaoqing Ju, Chunping Jia, Hui Cong
Circulating tumor cells (CTCs) exist in the peripheral blood and have an important role in the disease development, tumor metastasis and clinical surveillance, especially in the process of metastasis. However, the technology of detecting CTCs still had a large challenge since they were rare in the peripheral blood. Here, we developed a size-based microfluidic chip, which contained array and filter channel array that could enrich CTCs from blood samples more quickly and conveniently. Combined with clinical specimen, we analyzed CTCs in 200 lung cancer patients by this microfluidic chip...
February 14, 2018: Clinical and Experimental Medicine
https://www.readbyqxmd.com/read/29445602/uniportal-video-assisted-thoracoscopic-surgery-vats-sleeve-resections-for-non-small-cell-lung-cancer-patients-an-observational-prospective-study-and-technique-analysis
#14
Aris Koryllos, Erich Stoelben
Bronchus sleeve resection for operative treatment of non-small cell lung cancer (NSCLC) is a gold standard in modern thoracic surgery in cases of centrally located tumors or hilär lymph node metastases. Advanced instruments and growing surgical experience allowed surgeons to reduce the required incisions (from 3-port to uniportal) and to resect larger and more centrally located malignancies minimal invasively. It is a logical and expected advance in thoracic surgery that video-assisted thoracoscopic surgery (VATS) would be ultimately used also for complex bronchial resections...
2018: Journal of Visualized Surgery
https://www.readbyqxmd.com/read/29445601/predictors-of-unexpected-nodal-upstaging-in-patients-with-ct1-3n0-non-small-cell-lung-cancer-nsclc-submitted-to-thoracoscopic-lobectomy
#15
Giuseppe Marulli, Enrico Verderi, Giovanni M Comacchio, Nicola Monaci, Giuseppe Natale, Samuele Nicotra, Federico Rea
Background: In the last decades, the use of video-assisted thoracoscopic surgery (VATS) lobectomy for the treatment of early stage non-small cell lung cancer is continuously growing. This is mainly due to the development of more advanced surgical devices, to the rising incidence of peripheral lung tumors and is also favored by the increased reliability of preoperative staging techniques. Despite this progress, postoperative unexpected nodal upstaging is still a relevant issue. Aim of this study is to identify possible predictors of unexpected nodal upstaging in patients affected by cT1-3N0 NSCLC submitted to VATS lobectomy...
2018: Journal of Visualized Surgery
https://www.readbyqxmd.com/read/29443735/identification-of-gene-expression-models-for-laryngeal-squamous-cell-carcinoma-using-co-expression-network-analysis
#16
Chun-Wei Yang, Shu-Fang Wang, Xiang-Li Yang, Lin Wang, Lin Niu, Ji-Xiang Liu
One of the most common head and neck cancers is laryngeal squamous cell carcinoma (LSCC). LSCC exhibits high mortality rates and has a poor prognosis. The molecular mechanisms leading to the development and progression of LSCC are not entirely clear despite genetic and therapeutic advances and increased survival rates. In this study, a total of 116 differentially expressed genes (DEGs), including 11 upregulated genes and 105 downregulated genes, were screened from LSCC samples and compared with adjacent noncancerous...
February 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29442281/neutrophil-to-lymphocyte-ratio-as-an-early-marker-of-outcomes-in-patients-with-advanced-non-small-cell-lung-cancer-treated-with-nivolumab
#17
Aya Nakaya, Takayasu Kurata, Hiroshige Yoshioka, Yuki Takeyasu, Maiko Niki, Kayoko Kibata, Naoko Satsutani, Makoto Ogata, Takayuki Miyara, Shosaku Nomura
BACKGROUND: There is an unmet need to identify markers that predict the response to nivolumab in patients with non-small-cell lung cancer (NSCLC). The neutrophil-to-lymphocyte ratio (NLR) was recently recognized as an indicator of a poor prognosis in patients with various cancers. In the present study, we quantified the predictive impact of NLR in patients with NSCLC treated with nivolumab. METHODS: We retrospectively analyzed 101 patients with advanced NSCLC treated with nivolumab at Kansai Medical University Hospital from December 2015 to December 2016...
February 13, 2018: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29442139/safety-profile-of-nivolumab-administered-as-30-min-infusion-analysis-of-data-from-checkmate-153
#18
David Waterhouse, Leora Horn, Craig Reynolds, David Spigel, Jason Chandler, Tarek Mekhail, Mohamed Mohamed, Ben Creelan, Kenneth B Blankstein, Petros Nikolinakos, Michael J McCleod, Ang Li, Abderrahim Oukessou, Shruti Agrawal, Nivedita Aanur
PURPOSE: Nivolumab has been administered using a 60-min infusion time. Reducing this time to 30 min would benefit both patients and infusion facilities. This analysis compared the safety of 30- and 60-min infusions of nivolumab in patients with previously treated advanced non-small cell lung cancer. METHODS: CheckMate 153 is an open-label, phase 3b/4, predominantly community-based study ongoing in the United States and Canada. Patients with stage IIIB/IV disease with progression/recurrence after at least one prior systemic therapy received nivolumab 3 mg/kg every 2 weeks over 30 or 60 min for 1 year or until disease progression...
February 13, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29442014/improvement-of-treatment-outcomes-after-implementation-of-comprehensive-pharmaceutical-care-in-breast-cancer-patients-receiving-everolimus-and-exemestane
#19
M Todo, S Ueda, S Osaki, I Sugitani, T Takahashi, M Takahashi, H Makabe, T Saeki, Y Itoh
Combination therapy with everolimus and an aromatase inhibitor such as exemestane is an effective treatment option for advanced or recurrent breast cancer. However, the therapy is often limited because of the occurrence of severe adverse events (AEs), including oral mucositis, interstitial lung disease, diarrhea, and rash. Therefore, early management of AEs is extremely important to obtain maximum treatment outcome. We investigated here the effects of comprehensive pharmaceutical care for prevention of severe AEs on patient's quality-of-life (QOL) and continuation of therapy...
February 1, 2018: Die Pharmazie
https://www.readbyqxmd.com/read/29440919/efficacy-and-safety-of-cox-2-inhibitors-for-advanced-non-small-cell-lung-cancer-with-chemotherapy-a-meta-analysis
#20
Ping Dai, Jing Li, Xiao-Ping Ma, Jian Huang, Juan-Juan Meng, Ping Gong
Background: The study of cyclooxygenase-2 (COX-2) inhibitors is now mired in controversy. We performed a meta-analysis to assess the efficacy and safety profile of COX-2 inhibitors in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: A literature search of PubMed, EMBASE, the Cochrane Central databases, and ClinicalTrials.gov, up until March 26, 2017, identified relevant randomized controlled trials. Data analysis was performed using Stata 12...
2018: OncoTargets and Therapy
keyword
keyword
36943
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"